In Danaher's Cepheid GeneXpert systems, how do we prioritize test menu expansion versus improving turnaround time for existing assays?

Introduction

The trade-off between expanding the test menu and improving turnaround time for existing assays in Danaher's Cepheid GeneXpert systems presents a critical product strategy decision. This scenario involves balancing the breadth of diagnostic capabilities against the speed and efficiency of current tests. I'll analyze this trade-off by examining the product ecosystem, stakeholder impacts, and potential outcomes to provide a data-driven recommendation.

Step 1

Clarifying Questions (3 minutes)

• Based on market trends, I'm thinking test menu expansion might be driven by emerging infectious diseases. Could you provide insights on the current demand for new tests versus improvements in existing ones?

Why it matters: Helps prioritize development efforts based on market needs Expected answer: Balanced demand, with slight preference for new tests Impact on approach: Would influence resource allocation between new test development and existing test optimization

• Considering our business model, I assume improving turnaround time could significantly impact lab efficiency and cost-effectiveness. How does our pricing structure relate to test speed versus test variety?

Why it matters: Aligns product strategy with revenue model Expected answer: Premium pricing for faster results, volume-based pricing for test variety Impact on approach: Would inform positioning of speed improvements versus menu expansion

• Looking at user segments, I'm thinking different types of labs might prioritize speed versus variety differently. Can you share insights on our key customer segments and their preferences?

Why it matters: Ensures solution addresses diverse user needs Expected answer: Large hospitals prioritize variety, small clinics value speed Impact on approach: Might lead to a segmented strategy for different user groups

• Regarding technical feasibility, I'm curious about the complexity of improving turnaround time versus developing new tests. Could you provide an overview of the engineering challenges for each?

Why it matters: Assesses resource requirements and potential timelines Expected answer: Turnaround time improvements more complex, new tests more straightforward Impact on approach: Would influence short-term versus long-term strategy balancing

• Considering our current team structure, I'm wondering about our capacity for parallel development. How are our R&D teams currently allocated between new test development and system optimization?

Why it matters: Determines feasibility of pursuing both options simultaneously Expected answer: 70% new tests, 30% optimization Impact on approach: Might suggest reallocation of resources or phased approach